Scorpion Therapeutics
Last verified 2026-05-07. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $150.0Mattributed |
|---|---|
| Latest round | series-c, $150.0M, 2024-07-01attributed |
| Founded | unknown |
| Headquarters | Boston MA |
| Industry | biotech|oncology|therapeutics |
| Stage | series-b+ |
| Website | scorpiontx.com |
Scorpion Therapeutics is a clinical-stage precision-oncology biotech designing mutant-selective small molecules for patients with specific cancer driver mutations. It targets PI3K-alpha-mutant breast, gynecological, and other solid tumors. Lilly acquired the lead program STX-478 for up to $2.5B in milestones in early 2025.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-07-01 | series-c | $150.0M | lightspeed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series C, $150.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $150.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | scorpiontx.com, read 2026-05-07 |
| Description | self-reported | scorpiontx.com, read 2026-05-07 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.